| Year |
Citation |
Score |
| 2009 |
Laurie N, Mohan A, McEvoy J, Reed D, Zhang J, Schweers B, Ajioka I, Valentine V, Johnson D, Ellison D, Dyer MA. Changes in retinoblastoma cell adhesion associated with optic nerve invasion. Molecular and Cellular Biology. 29: 6268-82. PMID 19786571 DOI: 10.1128/Mcb.00374-09 |
0.453 |
|
| 2009 |
Shih CS, Laurie N, Holzmacher J, Spence Y, Nathwani AC, Davidoff AM, Dyer MA. AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Medicine. 11: 43-52. PMID 19306089 DOI: 10.1007/s12017-009-8059-0 |
0.453 |
|
| 2008 |
Laurie NA, Dyer MA, Shih CS. Targeting MDM2 and MDMX in retinoblastoma (Current Cancer Drug Targets (2007) 7, 7, (689-695)) Current Cancer Drug Targets. 8: 341. DOI: 10.2174/156800908784533472 |
0.409 |
|
| 2007 |
Laurie NA, Shih CS, Schin-Shih C, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Current Cancer Drug Targets. 7: 689-95. PMID 18045074 DOI: 10.2174/156800907782418266 |
0.483 |
|
| 2006 |
Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 444: 61-6. PMID 17080083 DOI: 10.1038/Nature05194 |
0.439 |
|
| 2005 |
Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, Egorin M, Stewart C, Dyer MA. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7569-78. PMID 16243833 DOI: 10.1158/1078-0432.Ccr-05-0849 |
0.467 |
|
| Show low-probability matches. |